section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

Rapidly Progressive Lysosomal Acid Lipase Deficiency Presenting within First 6 Mo of Age

Lysosomal Acid Lipase Deficiency in Children and Adults

US Brand Names

Kanuma

Action

  • A recombinant form of lysosomal acid lipase, it binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. It then catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol, and free fatty acids.
Therapeutic effects:
  • Improved survival in infants.
  • Improved lipids in adults and children.

Classifications

Therapeutic Classification: none assigned

Pharmacologic Classification: enzymes

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 5.4–6.6 min.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
IVUnknown1.3 hrUnknown



Patient/Family Teaching

Pronunciation

se-be-LYE-pase AL-fa